As partners of the summit, we will have our own virtual exhibit showroom - and we hope to see you there!
Here you will find more information about how we can help move Gene Therapy from a future promise to a reality.
Check-in and have a look around or take the opportunity to chat with our representatives at this event!
Our team of experts is available throughout the event and they are more than happy to answer any questions you might have. Take this opportunity to find out what answers we can provide to help out in your drug development or basic research projects.
In addition to our Talk and Poster we are very proud and extremely honored to fulfill our scientific agenda by leading a fully attended workshop: “Stability-Indicating Assays for AAV-Based Vectors”.
Michael G. Tovey, Ph.D, Chief Scientific Advisor of Svar Life Science France, will be leading the workshop on Mon, Nov 29.
"Stability-Indicating Assays for AAV-Based Vectors"
Join this workshop to discuss:
The poster will be available for download and is open for viewing and downloading during the entire summit. Our presenter has done a recording presenting the poster - please come by our booth and watch it!
In this poster we demonstrate the development of a technology, based upon the reporter gene assay format, that allows for assessment and quantification of the presence, activity, as well as function of a therapeutic AAV vector. Data is presented from a proprietary developed iLite® cGMP/GC reporter gene cell line and highlights examples from the development, validation, and utilization of the genetically modified custom cell line, the subsequent assay development, and the creation of assay-ready cells.
Highly sensitive assays, with an extended dynamic range, have been developed based on the iLite® reporter-gene technology for the quantification of the potency of AAV encoded transgenes regulated by photoreceptor-specific promoters without the need for helper virus or proteosome inhibitors.
A highly sensitive, rapid, and serotype specific assay for the quantification of neutralizing antibodies to recombinant AAV vectors based on the iLite® technology will also be presented